Loading company
Intellia Therapeutics, Inc.
NTLA · Nasdaq · ·
Next earnings: November 5, 2026
$12.04+5.3%Sep 29 close
- 1M
- -6.4%
- 6M
- +3.3%
- 1Y
- -30.3%
- 5Y
- -91.8%
NTLA · Nasdaq · ·
Next earnings: November 5, 2026
$12.04+5.3%Sep 29 close
Intellia Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $7.7M | $14.2M | -46.23% |
| Profit | -$106.6M | -$101.3M | -5.31% |
| Profit per share | -$0.80 | -$0.98 | +18.37% |
| Free Cash Flow | -$84.9M | -$99.9M | +14.96% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in hereditary angioedema,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Intellia Therapeutics, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Intellia Therapeutics, Inc. has no earnings call transcript available.